Valuation : SAB Biotherapeutics, Inc.

Market Cap 341M 294M 277M 253M 472M 32.23B 476M 3.28B 1.27B 16.48B 1.28B 1.25B 54.13B P/E 2026 *
-3.65x
P/E 2027 * -4.84x
Enterprise Value 86.47M 74.6M 70.28M 64.03M 120M 8.17B 121M 832M 323M 4.18B 325M 318M 13.72B EV / Sales 2026 *
-
EV / Sales 2027 * 1,031x
Free-Float
99.23%
Yield 2026 *
-
Yield 2027 * -
1 day-0.27%
1 week-4.58%
Current month+1.08%
1 month-1.06%
3 months+11.61%
6 months-3.60%
Current year+0.27%
1 week 3.6
Extreme 3.6
3.99
1 month 3.6
Extreme 3.6
3.99
Current year 3.28
Extreme 3.28
5.15
1 year 1.85
Extreme 1.85
5.15
3 years 1
Extreme 1
10.5
5 years 1
Extreme 1
129
10 years 1
Extreme 1
129
Manager TitleAgeSince
Chief Executive Officer 60 2014-06-30
Chief Executive Officer 51 2024-02-01
Director of Finance/CFO 40 2024-08-11
Director TitleAgeSince
Director/Board Member 79 2024-05-05
Director/Board Member 58 2023-04-02
Director/Board Member 70 2021-10-21
Date Insider Type Main position Quantity % Market Cap. Importance
3/24/26 Tax

Chief Technology Officer

988 0.0021%
2/5/26 Free

Chief Executive Officer

4,800,000 10.0826%
2/3/26 Free

Chief Technology Officer

2,400,000 5.0413%
Change 5-day change 1-year change 3-year change Capi.($)
-0.27%-4.58%+61.64%-45.65% 341M
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.13%+0.42%+49.28%+91.87% 65.29B
-0.69%+3.44%-12.50%+376.15% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-1.09%-7.60%+2.50%-15.63% 26.08B
+1.36%+1.52%+26.66%-17.39% 20.14B
-0.38%-17.67%+214.37%+373.18% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+0.84%+6.61%+59.40%+164.55% 14.5B
Average +0.57%-2.84%+48.21%+158.59% 28.07B
Weighted average by Cap. +0.78%-2.19%+41.98%+140.79%

Financials

2026 *2027 *
Net sales - 62.5K 53.92K 50.79K 46.28K 86.5K 5.9M 87.15K 601K 233K 3.02M 235K 230K 9.92M
Net income -85.34M -73.62M -69.35M -63.19M -118M -8.06B -119M -821M -319M -4.12B -320M -313M -13.54B -102M -87.59M -82.51M -75.17M -141M -9.59B -142M -977M -379M -4.9B -381M -373M -16.11B
Net Debt -255M -220M -207M -189M -353M -24.06B -355M -2.45B -951M -12.3B -957M -936M -40.41B -277M -239M -225M -205M -383M -26.15B -386M -2.66B -1.03B -13.37B -1.04B -1.02B -43.91B
Logo SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Employees
86
Date Price Change Volume
26-09-03 US$3.750 0.00% 20,729
26-09-02 US$3.750 +1.35% 300,420
26-09-01 US$3.700 -0.27% 202,282
26-08-31 US$3.710 -2.11% 201,144
26-08-28 US$3.790 -3.56% 202,596
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.750USD
Average target price
11.64USD
Spread / Average Target
+210.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SABS Stock